Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer
Essen Biotech's dual-target CAR-T therapy targeting Mesothelin and Claudin 18.2 represents a novel approach in treating advanced pancreatic adenocarcinoma, a malignancy with limited treatment options and poor prognosis. The dual-target strategy may enhance therapeutic efficacy by addressing antigen heterogeneity, potentially positioning Essen Biotech favorably in the competitive landscape of immunotherapies for pancreatic cancer. The market for pancreatic cancer therapies is growing, driven by increasing incidence rates and the need for effective treatments. Successful outcomes from this trial could lead to significant commercial opportunities, including partnerships, licensing agreements, and market exclusivity, contingent upon favorable safety and efficacy profiles.
Indication: Pancreatic Cancer
Modality: cell therapy
Target: Mesothelin and Claudin 18.2
Sponsor: Essen Biotech
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mesothelin and Claudin 18.2
View original source fields
Condition raw: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Condition normalized: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Mesothelin and Claudin 18.2
Target normalized: Mesothelin and Claudin 18.2